Melanoma: Risk factors and controversies

Clinical Risk

Volumn 15, Issue 1, 2009, Pages 3-7

  Bataille, Veronique ^a   Glass, Daniel ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649854649     PISSN: 13562622     EISSN: None     Source Type: Journal    
DOI: 10.1258/cr.2008.080090     Document Type: Article

References (47)

1. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008; 44: 1345-89.
2. Coory M, Baade P Aitken J, Smithers M, McLeod GR, Ring I. Trends for in situ and invasive melanoma in Queensland, Australia 1982-2002. Cancer Causes Control 2006; 17: 21-7.
3. Whiteman DC, Bray CA, Siskind V Green AC, Hole DJ, Mackie RM. Changes in the incidence of cutaneous melanoma in the west of Scotland and Queensland, Australia: hope for health promotion? Eur J Cancer Prev 2008; 17: 243-50.
4. Seettp://seer.cancer.gov/faststats/selections.php?run&output= 2&data= 1&statistic=2&year=200802&race=2&sex=1&age= 1&series=cancer& cancer=53.
5. Bliss JM, Ford D, Swerdlow AJ, et al. Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). IntJ Cancer 1995; 62: 367-76.
6. Cress RD, Holly EA. Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics,
7. Asians and blacks: an analysis of California Cancer Registry data, 1988 -93. Cancer Causes Control1997; 8: 246 -52.
8. Rouhani P Hu S, Kirsner RS. Melanoma in Hispanics and black Americans. Cancer Control 2008; 15: 248 -53.
9. Gandini S, Sera F Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur JCancer 2005; 41: 45 -60.
10. Bataille V, Boniol M, de Vries E, et al. A multicentre epidemiological study on sunbed use and cutaneous melanoma in Europe. Eur J Cancer 2005; 41: 2141 -49.
11. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA 2000; 283: 2975 -8.
12. de Vries E, Boniol M, Doré JF, Coeberg JWW; Eurocare working group. Lower incidence rates but thicker melanomas in Eastern Europe before 1992: a comparison with Western Europe. Eur J Cancer 2004; 40: 1045 -52.
13. Burton RC, Coates MS, Hersy P, et al. An analysis of a melanoma epidemic. Int J Cancer 1993; 55: 765 -70.
14. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 2005;331: 481.
15. Gordon L, Youl PH, Elwood M, et al. Diagnosis and management costs of suspicious lesions from a population-based melanoma screening programme. J Med Screen 2007; 14: 98 -102.
16. Perez-Gomez B, Aragones S, Gustavsson P, et al. Do sex and site matter? Different age distribution in melanoma of the trunk among Swedish men and women. Br J Dermatol 2008; 158: 766 -72.
17. Scoggins CR, Ross MI, Reintgen DS, et al. Gender-related differences in outcome for melanoma patients. Ann Surg 2006; 243:693-8; discussion 698 -700.
18. de Vries E, Nijsten E, Visser O, et al. Superior survival of females among 10,358 Dutch melanoma patients is independent of Breslow thickness,
19. histological type and tumor site. Ann Oncol 2008; 19: 583-9.
20. Bataille V, Kato BS, Falchi M, et al. Nevus size and number are associated with telomere length and represent potential markers of a reduced senescence in vivo. Cancer Epidemiol Biomarkers Prev 2007;16: 1499 -502.
21. Harrison S, MacKie R-M, MacLennan R. Development ofmelanocytic nevi in the first three years of life. J Natl Cancer Inst 2000; 92: 1436-8.
22. Bataille V, Snieder H, MacGregor AJ, Sasieni P, Spector TD. Genetics of risk factors for melanoma: an adult twin study of nevi and freckles. J Natl Cancer Inst 2000; 92: 457-63.
23. Wachsmuth RC, Gaut RM, Barrett JH, et al. Heritability and gene-environment interactions for melanocytic nevus density examined in a U.K. adolescent twin study. J Invest Dermatol 2001; 117: 348-52.
24. Bauer J, Buttner P Wiecker TS, Luther H, Garbe C. Interventional study in 1,232 young German children to prevent the development of melanocytic nevi failed to change sun exposure and sun protective behaviour. Int J Cancer 2005; 116: 755 -61.
25. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer.2005; 41: 28 -44.
26. Chang YM, Newton-Bishop JA, Bishop DT, et al. A pooled analysis of melanocytic naevus phenotype and the risk of cutaneous melanoma at different latitudes. Int J Cancer (in press).
27. ataille V, Sasieni P, Grulich A, et al. Solar keratoses: a risk factor for melanoma but negative association with melanocytic naevi. Int J Cancer 1998; 78: 8 -12.
28. Bataille V, Bishop JA, Sasieni P, et al. Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study.Br J Cancer 1996; 73: 1605 -11.
29. Newton Bishop JA and Gruis NA. Genetics: What advice for patients who present with a family history of melanoma? Semin Oncol 2007;34:452-59.
30. Bataille V. Genetic epidemiology of melanoma. Eur J Cancer 2003;39: 1341 -7.
31. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 and BRCA 2. A review of the literarure. J Clin Oncol 2004; 22: 735-42.
32. Gandini S, Sera F, Cattaruza MF, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005; 41: 2040-59.
33. Raimondi S, Sera F, Gandini S, et al. MCR1R variants, melanoma and red hair colour phenotype: a meta-analsysis. Int J Cancer 2008; 122: 2753 -60.
34. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2000; 27: 949 -54.
35. Whiteman DC, Watt P, Purdie DM, Hughes MC, Hayward NK, Green AC. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003; 95: 806 -12.
36. Wartman D, Weinstock M. Are we overemphasizing sun avoidance in protection from melanoma? Cancer Epidemiol Biomarkers Prev 2008;17:469-70.
37. Holick MF. Deficiency of sunlight and Vitamin D. BMJ 2008; 336 :1318-19.
38. Moan J, Porojnicu AC, Dahlback AC, Setlow RB. Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure. Pro Natl Acad Sci USA 2008; 105: 668 -73.
39. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392 -9.
40. Bieligk SC, Ghossein R, Bhattacharya S, Coit DG. Detection of tyrosinase mRNA by reverse transcription-polymerase chain reaction in melanoma sentinel nodes. Ann Surg Oncol 1999; 6: 232 40.
41. Scolyer RA, Murali R, McCarthy SW, Thompson JF. Pathologic examination of sentinel lymph nodes from melanoma patients. Semin Diagn Pathol 2008; 25: 100 -11.
42. Thomas JM, A'Hern RP, GrichnikJM, et al. Sentinel-node biopsy in melanoma. N Engl J Med 2007; 356: 418-.21.
43. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. JClin Oncol 2001; 19: 3635-.48.
44. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl JMed 2006; 355: 1307-.17.
45. Pizarro A. [Why does sentinel-node lymph node biopsy not increase survival in patients with melanoma?] Actas Dermosifiliogr 2008; 99:323-.30.
46. Cook MG, Di Palma S. Pathology of sentinel lymph nodes for melanoma. J Clin Pathol 2008; 61: 897-.902.
47. Medalie N, Ackerman AB. Sentinel node biopsy has no benefit for patients whose primary cutaneous melanoma has metastized to a lymph node and therefore should be abandoned now. Br J Dermatol2004; 151: 298-.307.